​​Lysosomal Therapeutics Inc.​​
Sanofi-Genzyme BioVentures (SGBV) is a strategic fund that invests primarily in early-stage life science companies developing innovative products that may become future Sanofi (EURONEXT: SAN and NYSE: SNY) products. SGBV provides not only financial support but also world class technical and strategic guidance through access to the Sanofi and Genzyme teams.

The Roche Venture Fund invests in innovative biotech and diagnostics companies to develop commercially successful life science companies.  Based in Basel with an office in South San Francisco, RVF is the corporate venture fund of the healthcare company Roche.  RVF invests globally with a portfolio of over 30 companies in North America and Europe. 


Delivering cures for neurodegenerative diseases. 

Atlas Venture is an early stage venture capital firm that invests in promising entrepreneurs focusing on life science and technology innovation. Based in Cambridge, Massachusetts we are focused on becoming the reference early stage investor in New England. We are contrarian, patient, and aggressive investors.

Angel Investors:

Orion Equity Partners, LLC

Mark Carthy, Managing Partner

Hatteras Venture Partners is a venture capital firm formed to invest primarily in early stage companies with a focus on biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. Founded in 2000 and based in Durham, NC, the Hatteras team brings operational experience, a successful track record, and a proven ability to enhance the value of the companies in which it invests. With four funds, the firm has approximately $250 million under management. 

Lilly Ventures has its roots in the scientific tradition of Eli Lilly and Company.  Our investment philosophy drives us to seek great companies with compelling life science innovations.  We partner actively with the management teams of our portfolio companies to realize the potential of their technologies.  Accordingly, we provide both financial and intellectual resources to accelerate the management teams’ path to success.  Lilly Ventures currently has $200 million under management with a focus on the North American and European regions. 

The Partners Innovation Fund is the strategic venture capital fund for Partners HealthCare, founded by the Massachusetts General Hospital and Brigham and Women’s Hospital. The mission of the fund is to provide the necessary support to commercialize innovations in medical informatics, diagnostics, drugs and devices that emerge from the Partners HealthCare investigator community.